ArticleWorld journal of urology2024
Transperineal laser ablation (TPLA) of the prostate for benign prostatic obstruction: the first 100 patients cohort of a prospective, single-center study.
Article in World journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06564415 (European Registry for Transperineal Laser Ablation of Prostate), which is not on this map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
European Registry for Transperineal Laser Ablation of Prostate (TPLA) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Obstruction (BPO)
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Transperineal laser ablation in the management of benign prostatic hyperplasia: an updated systematic review and pooled analysis.Prostate cancer and prostatic diseases · 2026Pooled it
- Transperineal Laser Ablation for Treatment of Lower Urinary Tract Symptoms in Benign Prostate Enlargement: A Systematic Review and Meta-analysis.International braz j urol : official journal of the Brazilian Society of UrologyPooled it
- Transperineal laser ablation for 300-gram benign prostatic hyperplasia in an inoperable high-risk patient: Expanding the therapeutic horizon.Urology case reports · 2026Article
- Comparison of Single Fiber Transperineal Laser Ablation and Radiofrequency Ablation in the Treatment of Benign Prostatic Hyperplasia.Cardiovascular and interventional radiology · 2026Article
- Sexual and urinary outcomes of minimally invasive surgical therapies for LUTS/BPH: a narrative review.International journal of impotence research · 2026Review
- Holmium laser enucleation of prostate via perineal urethrostomy for the treatment of benign prostatic hyperplasia with mild long segment stenosis of the anterior urethra.Langenbeck's archives of surgery · 2026Review
- State-of-the-art in minimally invasive treatments for benign prostatic obstruction.Investigative and clinical urology · 2026Review
- Freehand Ultrasound-Guided Transperineal Microwave Ablation for Benign Prostatic Hyperplasia: A Novel Application.Cureus · 2025Article
- Ultrasound-guided Transperineal Prostate Thermal Ablation (TPTA) for Benign Prostatic Hyperplasia: Feasibility of an Outpatient Procedure using Radiofrequency Ablation.Cardiovascular and interventional radiology · 2025Observational
- Real-World Clinical Outcomes of Transperineal Laser Ablation in BPH: A 12-Month Retrospective Analysis.Journal of clinical medicine · 2025Article
- Transperineal Focal Laser Ablation of the Prostate for Prostate Cancer: A Systematic Review of the Literature.Cancers · 2025Review
- Letter to the editor for the article "Transperineal laser ablation (TPLA) of the prostate for benign prostatic obstruction: the first 100 patients cohort of a prospective, single-center study".World journal of urology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTransperineal laser ablation (TPLA) is a new minimally-invasive surgical treatment for patients with benign prostatic obstruction (BPO). We report the perioperative and mid-term functional results of the first 100 consecutively patients undergoing TPLA at our institution.
methodsClinical data from consecutive patients undergoing TPLA at our institution from April 2021 to July 2023 were prospectively collected. Primary endpoints were the postoperative changes in IPSS, QoL and MSHQ 3-item questionnaires and in Qmax and post-void residual volume (PVR).
resultsOverall, 100 consecutive patients underwent the procedure. Median age and prostate volume were 66 (IQR 60-75) years and 50 (IQR 40-70) ml, respectively. In the cohort, 14 (14%) patients had an indwelling catheter and 81 (81%) were under oral BPO therapy at the time of TPLA. Baseline median Qmax (ml/s) and PVR (ml) were 9.1 (IQR 6.9-12) and 90 (IQR 50-150), respectively, while median IPSS and QoL were 18 (IQR 15-23) and 4 (IQR 3-4). At all the follow-up timepoints, the evaluated outcomes on both symptoms and functional parameters showed a statistically significant improvement (p < 0.001). Antegrade ejaculation was preserved in all sexually active patients. No postoperative Clavien-Dindo > 2 complications were recorded.
conclusionsTPLA represents a safe option for selected well-informed patients swith LUTS due to BPO. Our prospective study confirms the feasibility and favorable perioperative and functional outcomes in a real-world cohort with heterogenous prostate volumes and patient characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.